Guardant HealthMEX:GH 13 Days Payable is 56.27 as of Mar. 2026, which is 8% below its 10-year median of 61.46. GuruFocus rates MEX:GH with a GF Score™ of 13/100 and a GF Value™ of MXN1,017.70 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Guardant Health ranks worse than 64.21% on this metric.
The historical rank and industry rank for Guardant Health's Days Payable or its related term are showing as below:
MEX:GH'
s Days Payable Range Over the Past 10 Years
Min: 46.42 Med: 61.46 Max: 125.42
Current: 47.01
During the past 10 years, Guardant Health's highest Days Payable was 125.42. The lowest was 46.42. And the median was 61.46.
MEX:GH's Days Payable is ranked worse than 64.21% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs MEX:GH: 47.01
Guardant Health's Days Payable
increased
from Mar. 2025 (54.39) to Mar. 2026 (56.27).
It may suggest that Guardant Healthdelayed paying its suppliers.
Guardant Health Days Payable Related Terms
Guardant Health Days Payable Historical Data
* Premium members only.
The historical data trend for Guardant Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Guardant Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Guardant Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (MEX:GH) has a Days Payable of 56.27 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guardant Health and its competitors. This is near median its historical median of 61.46. Over the past decade, Guardant Health's Days Payable has ranged from 46.42 to 125.42. According to the industry distribution chart, Guardant Health ranks #122 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 64.2%.
Is Guardant Health's Days Payable too high?
Guardant Health's current Days Payable of 56.27 is near median its 10-year median of 61.46. Over the past 10 years, this metric has ranged from a low of 46.42 to a high of 125.42. The Medical Diagnostics & Research industry median Days Payable is 67.28. Guardant Health's value of 56.27 is 16.4% below this industry median. Based on the distribution chart, Guardant Health ranks #122 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Days Payable compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #122 out of 190 companies for Days Payable. This places Guardant Health in the lower half of its industry. The industry median Days Payable is 67.28. Guardant Health's value of 56.27 is 16.4% below this benchmark. Historically, Guardant Health's own Days Payable has ranged from 46.42 to 125.42 over the past decade. While the company's 10-year median is 61.46 vs. the industry median of 67.28, Guardant Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guardant Health's current Days Payable of 56.27 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current Days Payable is 56.27, which is near median its own 10-year median of 61.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN1,017.70, compared to a current price of MXN2,590.00 — trading 154.5% above its estimated fair value. The current Days Payable is 56.27, which is near median its 10-year median of 61.46 and 16.4% below the Medical Diagnostics & Research industry median of 67.28. Guardant Health's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current Days Payable is 56.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 154.5% above its estimated GF Value™ of MXN1,017.70.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for MEX:GH:
Days Payable: 56.27 (near median its 10-year median of 61.46)
GF Value™: MXN1,017.70 vs. price of MXN2,590.00 (154.5% above fair value)
Industry Position: 16.4% below the Medical Diagnostics & Research median (#122 of 190)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
